- Trials with a EudraCT protocol (193)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
193 result(s) found for: Pioglitazone.
Displaying page 6 of 10.
EudraCT Number: 2008-001634-28 | Sponsor Protocol Number: CVMD-DU-087 | Start Date*: 2008-11-11 | |||||||||||
Sponsor Name:University of Dundee | |||||||||||||
Full Title: Identification of genetic and functional biomarkers that predict PPAR-gamma-associated fluid retention and oedema | |||||||||||||
Medical condition: Patients with Type 2 diabetes mellitus (T2DM) whoa re not receiving insulin treatment | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-000833-12 | Sponsor Protocol Number: POLYCHEM | Start Date*: Information not available in EudraCT |
Sponsor Name:Azienda Ospedaliero-Universitaria di Parma | ||
Full Title: A prospective, randomized, parallel-group, adaptive design phase IIb/III, multicenter study, to assess the efficacy of polychemotherapy for inducing remission of newly diagnosed type 2 diabetes. | ||
Medical condition: type 2 diabetes mellitus | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: IT (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2009-012011-17 | Sponsor Protocol Number: H8O-MC-GWDE | Start Date*: 2009-11-19 | |||||||||||
Sponsor Name:Eli Lilly and Company | |||||||||||||
Full Title: Safety and Efficacy of Exenatide Once Weekly versus Liraglutide in subjects with type 2 diabetes and inadequate glycemic control treated with lifestyle modification and oral antidiabetic medications | |||||||||||||
Medical condition: Type 2 diabetes | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) DE (Completed) FR (Completed) ES (Completed) BE (Completed) SK (Completed) IT (Completed) AT (Completed) GR (Prematurely Ended) HU (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-004850-32 | Sponsor Protocol Number: EFC13794 | Start Date*: 2016-06-17 | |||||||||||
Sponsor Name:sanofi-aventis recherche & développement | |||||||||||||
Full Title: A 26-Week Randomized, Open-label, Active Controlled, Parallel-group, Study Assessing the Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination in Adults with Type 2 Diabe... | |||||||||||||
Medical condition: Type 2 Diabetes Mellitus | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SK (Completed) EE (Completed) ES (Completed) DE (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-006720-62 | Sponsor Protocol Number: 0431C-128 | Start Date*: 2009-04-21 | |||||||||||
Sponsor Name:Merck & Co., Inc. | |||||||||||||
Full Title: Ensayo clínico de fase III aleatorizado y controlado con placebo para estudiar la seguridad y la eficacia de la adición de sitagliptina (MK-0431) en pacientes con diabetes mellitus de tipo 2 que pr... | |||||||||||||
Medical condition: Diabetes Mellitus tipo 2 Type 2 diabetes mellitus | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) IT (Completed) GR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-002414-39 | Sponsor Protocol Number: MK-3102-018 | Start Date*: 2013-01-04 | |||||||||||
Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. | |||||||||||||
Full Title: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess Cardiovascular Outcomes Following Treatment with MK-3102 in Subjects with Type 2 Diabetes Mellitus | |||||||||||||
Medical condition: Type 2 Diabetes Mellitus | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) NL (Prematurely Ended) DE (Completed) NO (Completed) SE (Prematurely Ended) AT (Prematurely Ended) CZ (Completed) ES (Prematurely Ended) FI (Completed) DK (Prematurely Ended) IT (Completed) BE (Completed) SK (Prematurely Ended) LT (Prematurely Ended) PL (Prematurely Ended) FR (Prematurely Ended) HR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-007662-37 | Sponsor Protocol Number: GLP112755 | Start Date*: 2009-07-01 | |||||||||||
Sponsor Name:GlaxoSmithKline Research and Development Ltd. | |||||||||||||
Full Title: Estudio multicéntrico, aleatorizado, doble ciego, controlado con placebo y de grupos paralelos para determinar la eficacia y la seguridad de la albiglutida administrada en combinación con pioglitaz... | |||||||||||||
Medical condition: Diabetes mellitus de tipo 2 Type 2 Diabetes Mellitus | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-002968-24 | Sponsor Protocol Number: NN2211-3916 | Start Date*: 2012-04-20 | |||||||||||
Sponsor Name:Novo Nordisk A/S | |||||||||||||
Full Title: Efficacy and safety of liraglutide versus placebo as add-on to existing diabetes medication in subjects with type 2 diabetes and moderate renal impairment | |||||||||||||
Medical condition: Diabetes Mellitus, Type 2 | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-006706-14 | Sponsor Protocol Number: DE-PIO-028 | Start Date*: 2008-07-29 | |||||||||||
Sponsor Name:Takeda Pharma GmbH | |||||||||||||
Full Title: Impact of Pioglitazone, Metformin and the combination of both on cardiovascular risk in insulin-treated patients with Type 2 diabetes – The PIOcomb Study | |||||||||||||
Medical condition: Diabetes mellitus type 2 | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) AT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-016745-25 | Sponsor Protocol Number: AZ-SAX-001 | Start Date*: 2010-01-20 | |||||||||||
Sponsor Name:ikfe GmbH | |||||||||||||
Full Title: Investigation of a switch from Insulin Therapy to a metformin & saxagliptin combination in patients with type 2 diabetes mellitus | |||||||||||||
Medical condition: Type 2 Diabetes mellitus | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-002607-12 | Sponsor Protocol Number: JVSRS08 | Start Date*: 2008-08-08 |
Sponsor Name:Central Manchester& Manchester Children's University Hospitals NHS Trust | ||
Full Title: Sitagliptin vs sulphonylurea based treatments in Muslim patients with Type 2 diabetes during Ramadan | ||
Medical condition: Muslim patients with type 2 diabets fasting during Ramadan | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2006-001398-44 | Sponsor Protocol Number: PR 2006-04 | Start Date*: 2006-06-13 |
Sponsor Name:Barts and The London NHS Trust | ||
Full Title: The use of Peroxisome Proliferator Activator Receptor Agonists in the management of Androgen Independent Prostate Cancer | ||
Medical condition: The use of Peroxisome Proliferator Activator Receptor Agonists in the management of Androgen Independent Prostate Cancer. Open-labeled, non-randomised clinical trial in patients with androgen indep... | ||
Disease: | ||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male | |
Trial protocol: GB (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2007-002691-33 | Sponsor Protocol Number: H8O-MC-GWCD | Start Date*: 2007-07-11 |
Sponsor Name:Eli Lilly and Company Ltd | ||
Full Title: A Study to Assess the Effect of Exenatide Treatment on Mean 24-hour Heart Rate in Patients with Type 2 Diabetes | ||
Medical condition: Type 2 diabetes | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Completed) | ||
Trial results: View results |
EudraCT Number: 2013-003587-31 | Sponsor Protocol Number: MK8835-001 | Start Date*: 2014-04-03 | ||||||||||||||||
Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. | ||||||||||||||||||
Full Title: A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Ertugliflozin (MK-8835/PF-04971729) in Subjects with Type 2 Diabetes Mel... | ||||||||||||||||||
Medical condition: Type 2 Diabetes Mellitus with Stage 3 Chronic Kidney Disease Who Have Inadequate Glycemic Control on Background Antihyperglycemic Therapy | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (Completed) HU (Completed) BG (Completed) RO (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2009-013289-20 | Sponsor Protocol Number: 1218.61 | Start Date*: 2009-10-22 | ||||||||||||||||
Sponsor Name:Boehringer Ingelheim France | ||||||||||||||||||
Full Title: A Phase III, randomised, double-blind, placebo-controlled parallel group efficacy and safety study of linagliptin 5 mg administered orally once daily over 24 weeks in type 2 diabetic patients with ... | ||||||||||||||||||
Medical condition: Type 2 Diabetes Mellitus | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: FR (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2008-007664-42 | Sponsor Protocol Number: GLP112757 | Start Date*: 2009-09-14 | |||||||||||
Sponsor Name:GlaxoSmithKline LLC | |||||||||||||
Full Title: A Randomized, Double-Blind, Placebo- and Active-Controlled, Parallel-Group, Multicenter Study to Determine the Efficacy and Safety of Albiglutide Administered in Combination With Metformin and Glim... | |||||||||||||
Medical condition: Type 2 Diabetes Mellitus | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) ES (Completed) GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-012270-12 | Sponsor Protocol Number: BC22419 | Start Date*: 2010-05-21 | |||||||||||
Sponsor Name:F. Hoffmann-La Roche Ltd. | |||||||||||||
Full Title: Effects of 150 μg aleglitazar on renal function in patients with Type 2 diabetes and moderate renal impairment, as compared to Actos® | |||||||||||||
Medical condition: Type 2 diabetes with moderate renal function impairment | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) HU (Completed) SK (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-002367-21 | Sponsor Protocol Number: DiaSpax | Start Date*: 2021-11-01 | |||||||||||
Sponsor Name:Karolinska Universitetssjukhuset | |||||||||||||
Full Title: Fettvävsheterogenitet och dess koppling till typ 2 diabetes : En randomiserad öppen behandlingsstudie som jämför Empagliflozin, Pioglitazon och Semaglutide | |||||||||||||
Medical condition: Diabetes typ 2 | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-007027-14 | Sponsor Protocol Number: C06-27 | Start Date*: 2007-11-27 | |||||||||||
Sponsor Name:INSERM | |||||||||||||
Full Title: Influence du traitement par Pioglitazone sur l'Ostéoprotégérine dans le diabète de tye II | |||||||||||||
Medical condition: Diabète de type II | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-015816-17 | Sponsor Protocol Number: NN1250-3667 | Start Date*: 2010-07-20 | |||||||||||
Sponsor Name:Novo Nordisk A/S | |||||||||||||
Full Title: An extension trial to NN1250-3582 comparing safety and efficacy of NN1250 and insulin glargine, both with insulin aspart as meal-time insulin ± OADs in type 2 diabetes | |||||||||||||
Medical condition: Type 2 diabetes | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IE (Completed) DE (Completed) ES (Completed) IT (Completed) SK (Completed) BG (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
